In vitro anti-estrogenic potential of FertiZen-R™- a nutraceutical ingredient for estrogen modulation
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20230524Keywords:
FertiZen-R™, Infertility, MCF-7, Nutraceutical, PCOS, Reproductive healthAbstract
Background: According to CDC, polycystic ovarian syndrome (PCOS) is responsible for infertility in women with 6-12% incidences all over the world. The current treatment options available have several side effects such as amenorrhea and obesity amongst others. Dietary interventions such as non-estrogenic and androgen-suppressing foods along with nutraceutical products is considered for treating PCOS with minimum side effects. One such product of Zenherbs lab called FertiZen-R™ is a combination of three phytochemicals from three plants viz., Foeniculum vulgare, Linum Usitatissimum, Glycyrrhiza glabra, hibiscus extract and is developed as a product to treat and control PCOS.
Methods: The FertiZen-R™ was quantified for the presence of phytochemicals such as glycyrrhizic acid, polyphenols, and saponins. It was further tested for estrogenic/anti-estrogenic potential on estrogen-positive breast cancer cell line (MCF-7) using an E-Screen assay.
Results: The FertiZen-R™ showed presence of 5% glycyrrhizinic acid, 5% saponins, and 2-3% polyphenols. It exhibited a strong anti-estrogenic potential with 40-50% inhibition from concentrations as low as 0.156 mg/ml like tamoxifen (IC50 at 0.156 mg/ml), while inositol, a natural growth promoter, showed no effect on the cell viability.
Conclusions: FertiZen-R™ showed anti-estrogenic potential when tested in-vitro and can be used to treat PCOS in women even with ER-positive breast cancer cells. However, clinical studies to determine the dosage are required to warrant the potential of FertiZen-R™.
References
PCOS (Polycystic Ovary Syndrome) and Diabetes. Centers for Disease Control and Prevention, 2020. Available from: https://www.cdc.gov/diabetes/basics/ pcos.html. Accessed on 20 August 2022.
Franks S, McCarthy M, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2008;29(1):278-85.
Xu XL, Deng SL, Lian ZX, Yu K. Estrogen receptors in polycystic ovary syndrome. Cells. 2021;10(2):459.
Tang ZR, Xu XL, Deng SL, Lian ZX, Yu K. Oestrogenic endocrine disruptors in the placenta and the fetus. Int J Mol Sci. 2020;21(4):1519.
Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2001;138(1):38-44.
De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14(1):38.
Shields-Botella J, Chetrite G, Meschi S, Pasqualini J. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. J. Steroid Biochem Mol Biol. 2005;93:1-13.
van Meeuwen J, Korthagen N, de Jong P, Piersma A, van den Berg M. (Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture. Toxicol Appl Pharmacol. 2007;221(3):372-83.
Manzar N, Khan SA, Fatima N, Nisa MU, Ahmad MH, Afzal MI, et al. Exploring the prophylactic role of soy isoflavones against polycystic ovarian syndrome. Food Sci Amp Nutr. 2021;9(9):4738-44.
Meena M, Sharma M, Dhakar A, Singh C, Sharma L, Purvia R. Role of Foeniculum vulgare in PCOS- a review article. World J Pharm Res. 2019;8(10):344-50.
Mahboubi M. Foeniculum vulgareas: Valuable plant in management of women’s health. J Menopaus Med. 2019;25(1):1.
Jazani MA, Azgomi NDH, Azgomi NDA, Azgomi NDR. A comprehensive review of clinical studies with herbal medicine on polycystic ovary syndrome (PCOS). DARU J Pharm Sci. 2019;27(2):863-77.
Al-Snafi A. Glycyrrhiza glabra: a phytochemical and pharmacological review. IOSR J Pharm. 2018;8(6):1-17.
Saganuwan AH. Tropical plants with fertility and infertility value. Maturitas 2015;1(81):195-6.
Le Bail J, Varnat F, Nicolas J, Habrioux G. Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett. 1998;130(1-2):209-16.
Fonseca Martins AMCRPD, Hipólito M, Bach E, Zaidan Dagli ML, Garcia Bersano J, Lucena Cassiano LLBG, et al. E-screen assay validation: evaluation of estrogenic activity by MCF7 cell culture bioassay, in drinking water from different watersheds in state of São Paulo, Brazil. Int J Environ Agricult Res. 2017;3(5):36-42.
Deshmukh A, Pawar A, Tapre V, Parmar J, Deshmukh K. Comparison of gravimetric method with the colorimetric method for saponin content in safed musli (Chlorophytum borivilianum). Int J Horticult Food Sci. 20191(1):17-9.
Zhānghuìhuì LM. Method for determining glycyrrhizic acid content in extract after polysaccharide extraction of glycyrrhiza by virtue of vanillin-sulphuric acid, 2021 Available from: https://patents.google.com/patent/CN102621089A/en. Accessed on 20 August 2022.
Hashm Balaky H, Khalid K, Hasan A, Tahir S, Ubur S, Khedir A. Estimation of total tannin and total phenolic content in plant (Crataegus azarolus L) by orbital shaker technique. Int J Agricult Environ Food Sci. 2021;5(1):1-6.
Villalobos M, Olea N, Brotons JA, Olea-Serrano MF, Ruiz de Almodovar JM, Pedraza V. The E-screen assay: a comparison of different MCF7 cell stocks. Environ Health Perspect. 1995;103(9):844-50.
Ahmad NE, Abu Bakar MF, Suleiman M, Abu Bakar FI, Sabran SF, Kormin F. Antiproliferative activity of five Garcinia species collected in Sabah, Malaysian Borneo against estrogen receptor-human breast carcinoma (MCF-7) cell line. IOP Conference Series Earth Environ Sci. 2021;736(1):012004.
Resende FA, de Oliveira APS, de Camargo MS, Vilegas W, Varanda EA. Evaluation of estrogenic potential of flavonoids using a recombinant yeast strain and MCF7/BUS cell proliferation assay. PLoS One. 2013;8(10):e74881.
Ju YH, Doerge DR, Helferich WG. A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogen-dependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice. Food Chem Toxicol. 2008;46(1):310-20.
